George K. Ng
Insider Reports History
- Location
- San Diego, CA
- Signature
- /s/ George Ng, by John J. Wolfel, as Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by George K. Ng:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| TuHURA Biosciences, Inc./NV | Director | Options (Right to Buy) | 156,240 | $114,055 | $0.7300 | 12 Feb 2026 | Direct |
| Calidi Biotherapeutics, Inc. | Director | Common Stock | 18,542 | $33,376 | $1.80 | 12 Sep 2023 | Direct |
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Common Stock | 87,200 | $18,312 | $0.2100 | 24 Jul 2025 | George Ng IRRA FBO: George Ng |
| Calidi Biotherapeutics, Inc. | Director | Common Stock | 9,550 | $17,190 | $1.80 | 12 Sep 2023 | By Peng Ventures, LLC |
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Common Stock | 5,492 | $16,311 | $2.97 | 15 Apr 2026 | Direct |
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Common Stock | 3,488 | $10,045 | $2.88 | 15 Apr 2026 | George Ng IRRA FOB George Ng |
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Warrants | 43,600 | $9,156 | $0.2100 | 24 Jul 2025 | George Ng IRRA FBO: George Ng |
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Common Stock | 800 | $2,304 | $2.88 | 15 Apr 2026 | Ng Cha Family Trust |
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Stock Options (Right to Buy) | 768,000 | 01 Oct 2025 | Direct | ||
| Processa Pharmaceuticals, Inc. | Chief Executive Officer, Director | Restricted Stock Units | 256,000 | 01 Oct 2025 | Direct |
Insider Reports Filed by George K. Ng
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PCSA | Processa Pharmaceuticals, Inc. | 15 Apr 2026 | 1 | +$5,474 | 4 | Chief Executive Officer, Director | 17 Apr 2026, 16:54 |
| PCSA | Processa Pharmaceuticals, Inc. | 31 Mar 2026 | 1 | +$5,415 | 4 | Chief Executive Officer, Director | 01 Apr 2026, 17:15 |
| HURA | TuHURA Biosciences, Inc./NV | 12 Feb 2026 | 1 | $0 | 4 | Director | 17 Feb 2026, 16:19 |
| PCSA | Processa Pharmaceuticals, Inc. | 01 Oct 2025 | 2 | $0 | 4 | Chief Executive Officer, Director | 03 Oct 2025, 16:23 |
| PCSA | Processa Pharmaceuticals, Inc. | 24 Jul 2025 | 0 | $0 | 4/A | Chief Executive Officer, Director | 18 Sep 2025, 16:21 |
| PCSA | Processa Pharmaceuticals, Inc. | 27 Jan 2025 | 2 | $0 | 4/A | Chief Executive Officer, Director | 18 Feb 2025, 17:53 |
| HURA | TuHURA Biosciences, Inc./NV | 02 Jan 2025 | 1 | $0 | 4 | Director | 06 Jan 2025, 16:54 |
| HURA | Kintara Therapeutics, Inc. | 18 Oct 2024 | 3 | $0 | 4 | Director | 22 Oct 2024, 20:47 |
| HURA | Kintara Therapeutics, Inc. | 18 Oct 2024 | 0 | $0 | 3 | Director | 22 Oct 2024, 20:44 |
| PCSA | Processa Pharmaceuticals, Inc. | 30 Jan 2024 | 1 | +$27,000 | 4 | Chief Executive Officer, Director | 31 Jan 2024, 16:37 |
| PCSA | Processa Pharmaceuticals, Inc. | 12 Oct 2023 | 1 | +$25,000 | 4 | Chief Executive Officer, Director | 12 Oct 2023, 18:04 |
| PCSA | Processa Pharmaceuticals, Inc. | 10 Oct 2023 | 1 | +$25,000 | 4 | Chief Executive Officer, Director | 10 Oct 2023, 16:56 |
| CLDI | Calidi Biotherapeutics, Inc. | 12 Sep 2023 | 0 | $0 | 3 | Director | 25 Sep 2023, 18:39 |
| PCSA | Processa Pharmaceuticals, Inc. | 08 Aug 2023 | 2 | $0 | 4 | Chief Executive Officer | 09 Aug 2023, 16:51 |
| PCSA | Processa Pharmaceuticals, Inc. | 08 Aug 2023 | 0 | $0 | 3 | Chief Executive Officer | 09 Aug 2023, 16:47 |